Visiongain states that "Translational regenerative medicine market set to grow to $76bn by 2023".

London, UK, March 28, 2019 (GLOBE NEWSWIRE) -- The high potential earning for companies from products aimed at repairing organs and tissues has led to an increase in the attention given to regenerative medicine research. Regenerative medicine (RM) is viewed as possessing the ability to provide therapeutic products targeted at multiple disease classes, such as cardiovascular, dermatological, and orthopaedic conditions. Developments in stem cell therapies and tissue engineering in particular may catalyse rapid growth in the translational regenerative medicine market over the next decade and beyond.

For free sample pages on this report please click on:
https://www.visiongain.com/report/translational-regenerative-medicine-market-forecast-2019-2029/

The lead analyst of the report commented 'Regenerative medicine has become an area of competition between many national governments, particularly in Asia-Pacific. Partly, this is due to a desire to demonstrate excellence in national biotechnology industries, especially in emerging markets wanting to show progress in moving towards a knowledge-based economy. Governments are also concerned about obtaining a share in the global healthcare market of the future, when TRM products may be expected to overtake other types of treatment in the field of medicine, delivering both improved clinical outcomes and cost savings.?

If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 207 549 9987.

Leading companies featured in the report include Athersys, Inc., Avita Medical, AxoGen, Inc., MEDIPOST Co., Ltd., NuVasive, Astellas Pharma, Organogenesis Holdings Inc., Osiris Therapeutics, Inc. and others.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 207 549 9987.